Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -0.82% 121.50 120.00 123.00 123.50 121.50 123.50 20,437 10:07:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.0 -23.1 -8.4 - 188

Amryt Pharma Share Discussion Threads

Showing 5301 to 5322 of 5400 messages
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
DateSubjectAuthorDiscuss
10/12/2019
16:26
Why the slide on the share price
zingerburger
10/12/2019
16:25
Absolutely spot on Madlos
positivitynicholas
10/12/2019
10:41
FUM's product that failed phase3 was a potential cure for ED. Unfortunately it flopped! :-) I wonder if the same prospect of failure awaits AP101, purple11? Going by the number of AIM listed biotechs that have had drugs/treatments fail at the phase3 stage over the last few years I should say that the odds on success for AP101 are very slim indeed. Failure seems the more likely result. Just as well Wiley arranged the deal with Aegerion. At least now AMYT has 2 drugs that successfully passed phase3 and are generating significant, growing, revenue. The Amicus share price barely moved after it's equivalent to AP101 failed phase3. Let's hope the same could happen with the AMYT share price Merry Christmas to you, purple. I only hold a few AMYT. No other shares. I find it much more profitable to comment on the bb's of shares I don't own than buying them! :-)
papillon
10/12/2019
09:33
theres a lot of puppies around pappy.merry xmas
purple11
10/12/2019
09:32
O/T. Another heavily ramped biotech bites the dust! FUM currently down 72% today on a bad RNS.
papillon
09/12/2019
16:02
Wow!!!!!!!!!!!!!!!!! 2 massive trades and a large trade just gone through this afternoon. All sells and all timed at 14:22:39. 2 x 725k sells @ £1 valued at 2 x £725k = £1.5m and 100k sell @ £1 valued at £100k. That's £1.6m in total. I wonder if this is anything to do with the Novelion liquidation? I wonder if the share price will now recover now that these sells are out of the way?
papillon
05/12/2019
16:03
Yes, should complete recruitment this month and report in 1st Q
waterloo01
05/12/2019
15:52
Have we got a ball park time frame?
tiananmen
05/12/2019
15:45
? The phase 3 is actually quite close to readout in AP101
waterloo01
05/12/2019
14:58
As there is no sign of Phase III coming anytime soon for Amryt, my patience has run short. However, Futura Medical are due their Phase III results on MED 2005 in the next week or two. Their results are expected to be successful and currently trading at an attractive share price of 30p.This is expected to jump to 62p at a conservative estimate and Liberum has suggested it could reach £1.29 upon successful results.Worth considering as we wait for Amryt to gather momentum.https://www.proactiveinvestors.co.uk/companies/news/908286/futura-medical-worth-double-current-value-suggests-research-house-908286.html
tiananmen
05/12/2019
12:57
I did have 5,250, chica and tiananmen, but am now down to 4,000 having sold 250 weeks ago and another 1,000 (2 x 500) on Monday. I'll hang on to them as I'm still in profit having bought most of them at the equivalent of around 80p early this year. Where's the share price going for what remains of 2019? No idea as I can't predict share prices, or what, if any, news AMYT might come out with in the short term. A continuing gradual fall wouldn't surprise me until we get closer to the AP101 phase III results in 2020, but wtfdik?
papillon
05/12/2019
11:13
Have sold out myself, too many delays and no news, I will buy back in at a later stage and at an attractive price again
tiananmen
05/12/2019
11:07
I have to admit I have sold out yesterday.I bought shares here only for the AP103 Gene Therapy but I dont think we will see anything until 2025 at the earliest. They seem to be pumping 10's of million of Euro's into AP101 which I think is no better than an off the counter €6 bottle. (and I have done a comparison test myself,not scientific I know)
chica1
01/12/2019
21:53
"still only at .18 pence in old money so original investors are still down 25% even though the company has been 'transformed'" >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Just goes to show how overpriced AMYT were when they listed in May 2016, Bronxville. I'm baffled by the absence of the funds managed by Neil Woodford from the list of big percentage shareholders taking part in the initial 24p placing! LOL. After all Neil Woodford had a penchant for investing in biotech's that lost his funds money! I hate to admit this, but mdalos got his timing spot on when selling AMYT when he did.
papillon
01/12/2019
21:40
Bronxville Posts: 1,325 Price: 112.00 No Opinion RE: Papillion..no Nasdaq listing Today 17:20 Yep Pap and still only at .18 pence in old money so original investors are still down 25% even though the company has been 'transformed'... ++++ I'm still trying to figure why AP103 has fallen so far behind KB103.. Then again AP101 is a very tardy as well... >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> I'm gutted by the news that they currently have no plans to list on Nasdaq, Bronxville. Mug that I am I believed that they would fulfil their promise to list on Nasdaq within 90 days of the Aegerion deal being finalised. It's the only reason I'm still invested. Fortunately I'm still in profit, but for how long? I should have known better because Amryt have form when it comes to over promising.
papillon
01/12/2019
15:46
Bronxville Posts: 1,325 Price: 112.00 No Opinion Papillion..no Nasdaq listing Today 12:30 because there are still to many uncertainties... >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Well in that case, Bronxville, the company shouldn't make promises it's unable to fulfil!
papillon
30/11/2019
21:26
We were promised a Nasdaq listing within 90 days of the completion of the Aegerion deal. Amryt? Yet another AIM company that doesn't fulfil it's promises! I'm disappointed, but can't say I'm surprised. It is AIM after all! Cathal Friel went even further and stated that he expected the Nasdaq listing in October! I thought he meant October 2019! Silly me! He obviously meant October 2020, or maybe 2021, or 2022, or 2023, or ….! Friel needs to purchase a new crystal ball because his prediction has turned out to be rubbish!
papillon
30/11/2019
21:14
mdalos1 - 28 Nov 2019 - 10:14:35 - 5148 of 5158 Amryt Pharma - AMYT Just realised I'd have lost 20% of my Loot by now if I hadn't sold when I did. The CVRs are obviously worthless... but you never know.... some free money one day in the dim & distance future perhaps ? Did anybody work out just how many new shares would most likely be issued in order for a realistic US Nasdaq listing to take place and just how dilutive that exercise would be to existing AIM shareholders ?.. be careful what you wish for !!! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> "The CVR;s are obviously worthless" You could be right. We'll find out soon enough next year!
papillon
30/11/2019
15:22
I'm pretty sure diamondstar said early 2019 that AP103 was only 6 months behind KB103.
chica1
30/11/2019
13:29
I assume you're referring to KB103, Krystal's gene therapy for EB. They announced the KB103 clinical trial results back in June so I'm not sure how AP103 could ever have been just 6 months behind. Krystal's gene therapy uses a viral vector - the herpes simplex virus. The whole point about AP103 and what differentiates it from other gene therapies is the fact that it uses a synthetic polymer vector rather than a viral vector and so although Krystal's progress is interesting, surely it's no more relevant than any other gene therapy or indeed any other drug in development for EB?
bermudashorts
30/11/2019
12:33
Well that's better but I was under the impression that we were only 6 months to a year behind Krystal Biotech. It looks more like 3 years or more now.
chica1
30/11/2019
11:05
chica- It says 'clinical proof of concept expected by 2023' - the operative word being 'clinical'. In other words results of a phase I/IIa proof of concept trial by 2023. gnmartin - thanks for the link, appreciated.
bermudashorts
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200226 11:16:59